INSM Aug 2024 45.000 put
- Yahoo Finance Video
Insmed stock blasts off over lung condition study results
Insmed Incorporated (INSM) stock is skyrocketing as high as 110% in Tuesday's trading following positive results in the pharmaceutical company's study into treating chronic lung condition bronchiectasis. Market Domination Hosts Julie Hyman and Josh Lipton monitor Insmed's soaring stock price as it hopes to develop a range of use cases for a multitude of diseases. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
- PR Newswire
Insmed Announces Proposed $500 Million Public Offering of Common Stock
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to
- Investor's Business Daily
The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.
Insmed stock catapulted Tuesday after the biotech company's experimental lung disease treatment succeeded in a final-phase study.
